Get the Stockscreener App
5.405
0.09%
0.005
After Hours:
5.41
0.005
+0.09%
Dermata Therapeutics Inc stock is traded at $5.405, with a volume of 22,663.
It is up +0.09% in the last 24 hours and down -11.54% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$5.40
Open:
$5.2983
24h Volume:
22,663
Relative Volume:
1.07
Market Cap:
$3.68M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.2524
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
+2.82%
1M Performance:
-11.54%
6M Performance:
-55.70%
1Y Performance:
-62.72%
1-Day Range:
$5.285
$5.6999
1-Week Range:
$5.0413
$5.7391
52-Week Range:
$5.0413
$24.90
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
5.405 | 3.75M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Dermata Therapeutics Inc. stock daily chart insightsQuarterly Profit Summary & AI Enhanced Trading Signals - Newser
Live market analysis of Dermata Therapeutics Inc. Equity WarrantWeekly Investment Recap & Fast Entry Momentum Trade Alerts - Newser
Relative strength of Dermata Therapeutics Inc. Equity Warrant in sector analysis2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Can Dermata Therapeutics Inc. Equity Warrant recover in the next quarterProduct Launch & Advanced Technical Signal Analysis - Newser
Trend analysis for Dermata Therapeutics Inc. this weekEntry Point & Smart Investment Allocation Insights - Newser
Real time pattern detection on Dermata Therapeutics Inc. stockMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
Technical analysis overview for Dermata Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - Newser
Multi factor analysis applied to Dermata Therapeutics Inc. Equity Warrant2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - Newser
Dermata Therapeutics Inc. stock outlook for YEAR2025 Sector Review & Low Risk High Reward Ideas - Newser
What institutional flow reveals about Dermata Therapeutics Inc. Equity WarrantJuly 2025 PostEarnings & Community Verified Trade Signals - Newser
Using economic indicators to assess Dermata Therapeutics Inc. Equity Warrant potentialWeekly Profit Analysis & Free High Accuracy Swing Entry Alerts - Newser
Sentiment analysis tools applied to Dermata Therapeutics Inc.Market Volume Report & Long Hold Capital Preservation Tips - Newser
Dermata Therapeutics Inc. stock momentum explainedCEO Change & High Return Trade Opportunity Guides - Newser
Dermata Therapeutics Inc. Equity Warrant’s volatility index tracking explainedPortfolio Value Summary & Fast Exit and Entry Strategy Plans - Newser
Ranking Dermata Therapeutics Inc. Equity Warrant among high performing stocks via toolsJuly 2025 Patterns & Risk Controlled Swing Alerts - Newser
Using Bollinger Bands to evaluate Dermata Therapeutics Inc. Equity WarrantShort Setup & Daily Oversold Stock Bounce Ideas - Newser
Does Dermata Therapeutics Inc. show high probability of reboundQuarterly Growth Report & Fast Entry Momentum Trade Alerts - Newser
Regression analysis insights on Dermata Therapeutics Inc. performance2025 Technical Overview & Reliable Volume Spike Alerts - Newser
Has Dermata Therapeutics Inc. Equity Warrant found a price floorJuly 2025 Levels & Reliable Breakout Forecasts - Newser
Can momentum traders help lift Dermata Therapeutics Inc. Equity Warrant2025 Historical Comparison & Growth Oriented Trade Recommendations - Newser
Applying Wyckoff theory to Dermata Therapeutics Inc. Equity Warrant stockAnalyst Downgrade & Community Verified Watchlist Alerts - Newser
How to integrate Dermata Therapeutics Inc. Equity Warrant into portfolio analysis toolsSwing Trade & AI Driven Stock Price Forecasts - Newser
Can machine learning forecast Dermata Therapeutics Inc. recoveryWeekly Investment Report & Expert Curated Trade Ideas - Newser
Custom watchlist performance reports with Dermata Therapeutics Inc.Weekly Profit Summary & AI Optimized Trade Strategies - Newser
Leading vs lagging indicators on Dermata Therapeutics Inc. performanceTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
How to recover losses in Dermata Therapeutics Inc. Equity Warrant stockPortfolio Performance Report & Safe Capital Growth Plans - Newser
Forecasting Dermata Therapeutics Inc. Equity Warrant price range with options dataTrade Analysis Report & Fast Gain Stock Trading Tips - Newser
Signal strength of Dermata Therapeutics Inc. stock in tech scannersWeekly Stock Analysis & Free Community Supported Trade Ideas - Newser
Will breakout in Dermata Therapeutics Inc. Equity Warrant lead to full recovery2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
Is Dermata Therapeutics Inc. Equity Warrant a candidate for recovery playJuly 2025 Short Interest & Growth Focused Entry Reports - Newser
Using economic indicators to assess Dermata Therapeutics Inc. potentialJuly 2025 PreEarnings & Growth Focused Entry Point Reports - Newser
Tools to assess Dermata Therapeutics Inc. Equity Warrant’s risk profileTrade Analysis Summary & Real-Time Buy Zone Alerts - Newser
Can Dermata Therapeutics Inc. Equity Warrant hit a new high this monthJuly 2025 Pullbacks & Free Growth Oriented Trading Recommendations - Newser
Dermata shifts focus to OTC skin care products, abandons prescription drug - Investing.com
Dermata Therapeutics announces strategic pivot to OTC skin care treatments - TipRanks
Dermata Therapeutics withdraws IND application for XYNGARI - TipRanks
Dermata withdraws FDA application for Xyngari, shifts focus to OTC skin care - MarketScreener
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments - ACCESS Newswire
50 Million Patient Market: Dermata's Strategic Shift to OTC Could Revolutionize Acne Treatment Access - Stock Titan
How to build a custom watchlist for Dermata Therapeutics Inc. Equity WarrantWeekly Market Outlook & Precise Buy Zone Tips - Newser
Key metrics from Dermata Therapeutics Inc.’s quarterly dataMarket Performance Recap & Capital Efficiency Focused Ideas - Newser
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):